Scribe Therapeutics Inc. announced that co-founder and CEO Benjamin Oakes, Ph.D., and CFO David Parrot will participate in the upcoming Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and Wednesday, March 13, 2024 in Miami Beach, FL.
ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that co-founder and CEO Benjamin Oakes, Ph.D., and CFO David Parrot will participate in the upcoming Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and Wednesday, March 13, 2024 in Miami Beach, FL.
About Scribe Therapeutics
Scribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306308442/en/
Investor Contact:
Stern IR for Scribe Therapeutics
investors@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
Source: Scribe Therapeutics Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240306308442/en
